4331 related articles for article (PubMed ID: 30872561)
41. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
42. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
[TBL] [Abstract][Full Text] [Related]
43. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
44. Choice of management of southern Chinese BRCA mutation carriers.
Kwong A; Wong CH; Shea C; Suen DT; Choi CL
World J Surg; 2010 Jul; 34(7):1416-26. PubMed ID: 20182723
[TBL] [Abstract][Full Text] [Related]
45. Timing of prophylactic hysterectomy-oophorectomy, mastectomy, and microsurgical breast reconstruction in BRCA1 and BRCA2 carriers.
Khansa I; Wang D; Coriddi M; Tiwari P
Microsurgery; 2014 May; 34(4):271-6. PubMed ID: 24123194
[TBL] [Abstract][Full Text] [Related]
46. Defining a place for nipple sparing mastectomy in modern breast care: an evidence based review.
Murthy V; Chamberlain RS
Breast J; 2013; 19(6):571-81. PubMed ID: 22284266
[TBL] [Abstract][Full Text] [Related]
47. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
48. BRCA mutation genetic testing implications in the United States.
Bayraktar S; Arun B
Breast; 2017 Feb; 31():224-232. PubMed ID: 27931006
[TBL] [Abstract][Full Text] [Related]
49. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
50. Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
Allué Cabañuz M; Domingo Bretón M; Chóliz Ezquerro J; Arribas Del Amo MD; Güemes Sánchez AT
Cir Esp (Engl Ed); 2020 Dec; 98(10):612-617. PubMed ID: 32505558
[TBL] [Abstract][Full Text] [Related]
51. Multidisciplinary management of mammary Paget's disease: recommendations to optimize oncological and aesthetic outcomes.
Franceschini G; Mason EJ; Di Leone A; Scardina L; Masetti R
Ann Ital Chir; 2022; 93():481-482. PubMed ID: 36196555
[TBL] [Abstract][Full Text] [Related]
52. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
53. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
[TBL] [Abstract][Full Text] [Related]
54. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
Li X; You R; Wang X; Liu C; Xu Z; Zhou J; Yu B; Xu T; Cai H; Zou Q
Clin Cancer Res; 2016 Aug; 22(15):3971-81. PubMed ID: 26979395
[TBL] [Abstract][Full Text] [Related]
55. Breast cancer prevention in high-risk women.
Thorat MA; Balasubramanian R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():18-31. PubMed ID: 31862315
[TBL] [Abstract][Full Text] [Related]
56. Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
Valero MG; Moo TA; Muhsen S; Zabor EC; Stempel M; Pusic A; Gemignani ML; Morrow M; Sacchini V
Br J Surg; 2020 Sep; 107(10):1307-1312. PubMed ID: 32432359
[TBL] [Abstract][Full Text] [Related]
57. Optimizing the total skin-sparing mastectomy.
Wijayanayagam A; Kumar AS; Foster RD; Esserman LJ
Arch Surg; 2008 Jan; 143(1):38-45; discussion 45. PubMed ID: 18209151
[TBL] [Abstract][Full Text] [Related]
58. Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.
Grinstein O; Krug B; Hellmic M; Siedek F; Malter W; Burke C; Schmutzler R; Maintz D; Rhiem K
Surg Oncol; 2019 Jun; 29():126-133. PubMed ID: 31196476
[TBL] [Abstract][Full Text] [Related]
59. Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
Kearton S; Wills K; Bunting M; Blomfield P; James PA; Burke J
Fam Cancer; 2018 Jul; 17(3):333-344. PubMed ID: 29039136
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
